Eduardo Candelario-Jalil Selected Research

nimesulide (Aulin)

4/2008	Nimesulide as a promising neuroprotectant in brain ischemia: new experimental evidences.
2/2007	Post-ischaemic treatment with the cyclooxygenase-2 inhibitor nimesulide reduces blood-brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in rats.
1/2005	Effects of the cyclooxygenase-2 inhibitor nimesulide on cerebral infarction and neurological deficits induced by permanent middle cerebral artery occlusion in the rat.
5/2004	Wide therapeutic time window for nimesulide neuroprotection in a model of transient focal cerebral ischemia in the rat.
10/2003	Delayed treatment with nimesulide reduces measures of oxidative stress following global ischemic brain injury in gerbils.
10/2002	Neuroprotective efficacy of nimesulide against hippocampal neuronal damage following transient forebrain ischemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eduardo Candelario-Jalil Research Topics

Disease

24	Ischemic Stroke 11/2021 - 11/2003
23	Stroke (Strokes) 06/2022 - 05/2004
18	Ischemia 01/2020 - 02/2002
17	Brain Injuries (Brain Injury) 01/2022 - 02/2002
17	Brain Ischemia (Cerebral Ischemia) 01/2020 - 10/2002
12	Infarction (Infarctions) 01/2019 - 11/2003
10	Neuroinflammatory Diseases 01/2021 - 04/2009
9	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2017 - 11/2003
7	Inflammation (Inflammations) 06/2022 - 07/2008
4	Alzheimer Disease (Alzheimer's Disease) 12/2019 - 02/2006
4	Edema (Dropsy) 04/2014 - 11/2007
3	Hypoxia (Hypoxemia) 01/2017 - 11/2013
3	Cerebral Infarction 02/2008 - 05/2004
3	Reperfusion Injury 02/2008 - 04/2002
2	Prion Diseases (Transmissible Spongiform Encephalopathies) 10/2021 - 02/2006
2	Herpes Zoster 01/2018 - 04/2014
2	Neuroblastoma 11/2017 - 09/2009
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2010 - 08/2005
2	Necrosis 08/2008 - 07/2008
2	Encephalitis (Encephalitis, Rasmussen) 02/2006 - 08/2005
2	Astrocytoma (Pilocytic Astrocytoma) 02/2006 - 05/2005
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2021
1	Scrapie 10/2021
1	Dementia (Dementias) 08/2021
1	Central Nervous System Diseases (CNS Diseases) 01/2021
1	COVID-19 12/2020
1	Disease Progression 12/2019
1	Gliosis 12/2019
1	Memory Disorders (Memory Loss) 12/2019
1	Parkinson Disease (Parkinson's Disease) 11/2017
1	Pulmonary Hypertension 01/2017
1	Weight Loss (Weight Reduction) 01/2017

Drug/Important Bio-Agent (IBA)

11	Matrix Metalloproteinases (MMPs)IBA 01/2022 - 11/2007
11	Neuroprotective AgentsIBA 11/2021 - 10/2003
7	Proteins (Proteins, Gene)FDA Link 06/2022 - 01/2017
7	ProstaglandinsIBA 01/2018 - 08/2005
6	nimesulide (Aulin)IBA 04/2008 - 10/2002
6	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 02/2007 - 02/2002
5	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2020 - 05/2004
5	Dinoprostone (PGE2)FDA Link 12/2015 - 08/2003
4	Peptides (Polypeptides)IBA 11/2021 - 11/2013
3	CytokinesIBA 06/2022 - 01/2017
3	Tyrosine (L-Tyrosine)FDA Link 01/2021 - 11/2013
3	p38 Mitogen-Activated Protein KinasesIBA 01/2021 - 05/2005
3	Pharmaceutical PreparationsIBA 01/2021 - 02/2008
3	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2020 - 11/2007
3	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2019 - 03/2013
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2008 - 11/2007
3	Prostaglandins EIBA 08/2008 - 05/2004
2	Interleukin-6 (Interleukin 6)IBA 06/2022 - 05/2005
2	ChemokinesIBA 06/2022 - 01/2019
2	Protein Isoforms (Isoforms)IBA 10/2021 - 08/2003
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2021 - 11/2013
2	OccludinIBA 01/2020 - 01/2018
2	Tight Junction ProteinsIBA 01/2018 - 04/2014
2	methyl ester 5(S),6(R)-7-trihydroxyheptanoic acidIBA 01/2017 - 04/2014
2	LipidsIBA 01/2017 - 10/2003
2	Glucose (Dextrose)FDA LinkGeneric 01/2017 - 01/2016
2	lipoxin A4IBA 01/2017 - 04/2014
2	ResveratrolIBA 09/2009 - 10/2007
2	EnzymesIBA 09/2009 - 01/2008
2	Interleukin-1beta (Interleukin 1 beta)IBA 08/2008 - 02/2006
2	Serotonin (5 Hydroxytryptamine)IBA 08/2008 - 05/2005
2	Malondialdehyde (Propanedial)IBA 07/2008 - 10/2003
2	Peroxidase (Myeloperoxidase)IBA 07/2008 - 02/2007
2	AntioxidantsIBA 07/2008 - 10/2005
2	SalicylatesIBA 02/2007 - 08/2003
2	OzoneIBA 10/2005 - 04/2002
2	Glutathione (Reduced Glutathione)IBA 10/2003 - 08/2003
1	4-hydroxy-2-nonenal (4-hydroxynonenal)IBA 06/2022
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 06/2022
1	Cell Adhesion MoleculesIBA 01/2022
1	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 11/2021
1	Prion ProteinsIBA 10/2021
1	Messenger RNA (mRNA)IBA 08/2021
1	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2021
1	Angiotensin-Converting Enzyme 2IBA 12/2020
1	Nucleocapsid ProteinsIBA 12/2020
1	Indicators and Reagents (Reagents)IBA 12/2020
1	Small Cytoplasmic RNAIBA 12/2020
1	3- cyano- N- (1,3- diphenyl- 1H- pyrazol- 5- yl)benzamideIBA 12/2019
1	LipopolysaccharidesIBA 05/2019
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019
1	(+)-JQ1 compoundIBA 01/2019
1	Proteolysis Targeting ChimeraIBA 01/2019
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2019
1	LigandsIBA 01/2019
1	snake venom protein C activatorIBA 01/2019
1	Oxygen (Dioxygen)IBA 01/2018
1	L-902688IBA 01/2018
1	1- trichloromethyl- 1,2,3,4- tetrahydro- beta- carbolineIBA 11/2017
1	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 11/2017
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2017
1	(4- ((5,6- diphenylpyrazin- 2- yl)(isopropyl)amino)butoxy)acetic acidIBA 01/2017

Therapy/Procedure

9	Therapeutics 11/2021 - 10/2005
3	Intravenous Injections 01/2018 - 04/2014
3	Treatment Delay 01/2005 - 10/2003
2	Intravenous Administration 01/2021 - 04/2014
1	Thrombectomy 01/2021
1	Mechanical Thrombolysis 01/2021